Monograph

D11AH01 - Tacrolimus

Propably not porphyrinogenic

Rationale

Substrate for CYP 3A4. Strong clinical inhibitor of CYP 3A4 and 1A. Probably insignificant systemic exposure.

Chemical description

Tacrolimus salve 0.1-0.03 % used in atopic dermatitis. Minimal percutaneous absorbtion, blood concentrations in dermal use <1 ng/mL. Metabolized in the liver by CYP 3A4. One report of uneventful systemic use in one patient with AIP. See: Turton-Weeks et al. Prog Transplant 2001 Sept;11(3):214-216)

IPNet drug reports

Uneventful use reported in 2 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes D11A / D11AH or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames